Indications and applicable groups of fezolinetant

Fezolinetant is a new neurokinin 3 (NK3) receptor antagonist that represents a precise targeted treatment direction for the management of menopausalvasomotor symptoms (VMS). Vasomotor symptoms, including hot flashes, night sweats and related sleep disorders, are common bothersome symptoms in menopausal and perimenopausal women and seriously affect their quality of life. By selectively inhibiting the hypothalamic neurokinin 3 (NK3) receptor, Fezonatant regulates the signaling pathway in the body temperature control center, thereby alleviating the frequency and intensity of hot flashes without introducing additional changes in estrogen or progesterone levels like traditional hormone therapy.

The applicable population is mainly adult women who have experienced natural menopause or surgical menopause, especially those with moderate to severe vasomotor symptoms that significantly affect their daily life and sleep quality. Overseas clinical studies have shown that after using fezonatant, the number of hot flashes in such patients was significantly reduced, the severity of night sweats was also controlled, and the overall quality of life and sleep experience were significantly improved. The targeting mechanism of nonazonatant allows it to be effective without the need for estrogen supplementation, which is especially suitable for people who cannot accept hormone replacement therapy (such as those at high risk of breast cancer and those with a history of thrombosis).

The pharmacological properties of Fezonatant also show that it has a relatively mild effect and good safety. Common adverse reactions are mainly mild headache or mild gastrointestinal discomfort, and most patients can tolerate it in the early stages of medication. The dosage and usage period of the drug are usually individually adjusted by doctors based on the patient's symptom severity and tolerance to ensure the best balance of efficacy and safety in long-term use. With the accumulation of more clinical experience, fezonatant has gradually become an important choice for the management of vasomotor symptoms, providing a non-hormonal, targeted and precise treatment option for menopausal women.

Reference materials:https://www.veozah.com/